TY - JOUR
T1 - Neurofibromatosis type 1 associated low grade gliomas
T2 - A comparison with sporadic low grade gliomas
AU - Helfferich, Jelte
AU - Nijmeijer, Ronald
AU - Brouwer, Oebele F
AU - Boon, Maartje
AU - Fock, Annemarie
AU - Hoving, Eelco W
AU - Meijer, Lisethe
AU - den Dunnen, Wilfred F A
AU - de Bont, Eveline S J M
N1 - Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, associated with a variable clinical phenotype including café-au-lait spots, intertriginous freckling, Lisch nodules, neurofibromas, optic pathway gliomas and distinctive bony lesions. NF1 is caused by a mutation in the NF1 gene, which codes for neurofibromin, a large protein involved in the MAPK- and the mTOR-pathway through RAS-RAF signalling. NF1 is a known tumour predisposition syndrome, associated with different tumours of the nervous system including low grade gliomas (LGGs) in the paediatric population. The focus of this review is on grade I pilocytic astrocytomas (PAs), the most commonly observed histologic subtype of low grade gliomas in NF1. Clinically, these PAs have a better prognosis and show different localisation patterns than their sporadic counterparts, which are most commonly associated with a KIAA1549:BRAF fusion. In this review, possible mechanisms of tumourigenesis in LGGs with and without NF1 will be discussed, including the contribution of different signalling pathways and tumour microenvironment. Furthermore we will discuss how increased understanding of tumourigenesis may lead to new potential targets for treatment.
AB - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, associated with a variable clinical phenotype including café-au-lait spots, intertriginous freckling, Lisch nodules, neurofibromas, optic pathway gliomas and distinctive bony lesions. NF1 is caused by a mutation in the NF1 gene, which codes for neurofibromin, a large protein involved in the MAPK- and the mTOR-pathway through RAS-RAF signalling. NF1 is a known tumour predisposition syndrome, associated with different tumours of the nervous system including low grade gliomas (LGGs) in the paediatric population. The focus of this review is on grade I pilocytic astrocytomas (PAs), the most commonly observed histologic subtype of low grade gliomas in NF1. Clinically, these PAs have a better prognosis and show different localisation patterns than their sporadic counterparts, which are most commonly associated with a KIAA1549:BRAF fusion. In this review, possible mechanisms of tumourigenesis in LGGs with and without NF1 will be discussed, including the contribution of different signalling pathways and tumour microenvironment. Furthermore we will discuss how increased understanding of tumourigenesis may lead to new potential targets for treatment.
KW - Animals
KW - Glioma/diagnosis
KW - Humans
KW - Mutation
KW - Neoplasm Grading
KW - Neurofibromatosis 1/complications
KW - Phenotype
KW - Signal Transduction
KW - Tumor Microenvironment
UR - http://www.scopus.com/inward/record.url?scp=84976465873&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2016.05.008
DO - 10.1016/j.critrevonc.2016.05.008
M3 - Review article
C2 - 27263935
SN - 1040-8428
VL - 104
SP - 30
EP - 41
JO - Critical reviews in oncology/hematology
JF - Critical reviews in oncology/hematology
ER -